REG - Sareum Holdings PLC - Results of AGM

Sareum HoldingsAnnouncement

14/12/2023 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231214:nRSN8859Wa&default-theme=true

RNS Number : 8859W  Sareum Holdings PLC  14 December 2023

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 14 December 2023 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, held its Annual General Meeting ("AGM") today
and all resolutions were duly passed. Voting was conducted by a show of hands
and inclusive of votes received by the Company by way of proxy.

 

Details of the proxy voting results are shown in the table below.

 

 Ordinary Resolutions                                                    Votes For  %      Votes Against  %     Votes Total  % of ISC Voted  Votes Withheld
 1. Receive the financial statements for the year                        4,955,805  99.3%  33,480         0.7%  4,989,285    7.1%            2,917
 2. Receive and approve the Directors' Renumeration Report for the year  4,797,240  96.2%  187,995        3.8%  4,985,235    7.1%            6,967
 3. Re-elect Dr Timothy Mitchell as Director of the Company              4,723,539  94.9%  256,139        5.1%  4,979,678    7.1%            12,524
 4. Re-elect Dr Stephen Parker as Director of the Company                4,569,986  92.0%  399,292        8.0%  4,969,278    7.1%            22,924
 5. Re-appoint Shipleys LLP as auditor                                   4,855,004  98.1%  92,757         1.9%  4,947,761    7.0%            44,441
 6. Authorise the audit committee to determine auditor renumeration      4,867,151  98.3%  86,553         1.7%  4,953,704    7.1%            38,498
 7. Directors' authority to allot new shares                             4,567,808  92.4%  373,843        7.6%  4,941,651    7.0%            50,551
 Special Resolution
 8. Directors' authority to disapply pre-emption rights                  4,573,097  92.5%  368,554        7.5%  4,941,651    7.0%            50,551
 9. Authority to hold general meetings                                   4,926,142  99.0%  49,243         1.0%  4,975,385    7.1%            16,817

ISC - Issued Share Capital

 

The full text of each of the resolutions is set out in the Notice of AGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/) )

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFFDFILEDSEDE